

---

## Product Data Sheet

---

Product Name: Atraric acid

Cat. No.: GC66207

### Chemical Properties

Cas. No. 4707-47-5

Formula  $C_{10}H_{12}O_4$

M.Wt 196.2

Solubility DMSO : 100 mg/mL (509.68 mM; Need ultrasonic)

Storage 4°C, stored under nitrogen

General tips For obtaining a higher solubility , please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request.

Structure

### Background

Atraric acid (Methyl atrarate) is a specific **androgen receptor (AR)** antagonist with anti-inflammatory and anticancer effects. Atraric acid represses the expression of the endogenous prostate specific antigen gene in both LNCaP and C4-2 cells. Atraric acid can also inhibit the synthesis of **NO** and cytokine, and suppress the **MAPK-NFκB** signaling pathway. Atraric acid can be used to research prostate diseases and inflammatory diseases<sup>[1][2]</sup>.

Atraric acid (10 μM; CV1 cells) represses the transactivation function mediated by Dihydrotestosterone-induced human AR<sup>[1]</sup>.

Atraric acid (10 μM; PCa cells) inhibits the expression of the PSA gene in both androgen-dependent and androgen-independent PCa cells<sup>[1]</sup>.

Atraric acid (1-300 μM; 24 h) dose-dependently inhibits pro-inflammatory cytokine, nitric oxide, prostaglandin E2 in LPS-stimulated RAW264.7 cells, but does not influence the cell viability<sup>[2]</sup>.

Atraric acid (100 and 300 μM; 18 h or 4 h) downregulates the expression of phosphorylated IκB, extracellular signal-regulated kinases (ERK) and nuclear factor

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

**Product Data Sheet**

---

kappa B (NFκB) signaling pathway to exhibit anti-inflammatory effects in LPS-stimulated RAW264.7 cells<sup>[2]</sup>.

**Cell Viability Assay<sup>[2]</sup>**

Cell Line: RAW264.7 cells  
Concentration: 1-300 μM  
Incubation Time: 24 h  
Result: Did not influence the cell viability.

**Western Blot Analysis<sup>[2]</sup>**

Cell Line: RAW264.7 cells  
Concentration: 100 and 300 μM  
Incubation Time: 18 h or 4 h  
Result: Inhibited LPS-Induced expression of iNOS and COX-2 in a dose-dependent manner. Suppressed LPS-stimulated phosphorylation of the Nfkb signaling pathway.

Atraric acid (10, 30 mg/kg; i.p.; single dosage) inhibits the production of pro-inflammatory cytokines and reduces pathological damages in LPS-induced endotoxin shock mice<sup>[2]</sup>.

Animal Model: Female BALB/c mice (7 weeks old, 17-20 g; LPS-induced endotoxin shock)<sup>[2]</sup>  
Dosage: 10, 30 mg/kg

Administration: i.p.; single dosage

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

---

---

## Product Data Sheet

---

Result: Inhibited the production of pro-inflammatory cytokines.Reduced pathological damages such as vasodilation and bleeding.

**Caution: Product has not been fully validated for medical applications. For research use only.**

**Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com**

**Address: 10292 Central Ave. #205, Montclair, CA, USA**